Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF)

Journal of Clinical Ligand Assay

Volumn 23, Issue 3, 2000, Pages 193-205

  Stiver, S I ^a   Dvorak, H F ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Endothelium; Immunoassay; Quantitation; Vascular permeability factor; VEGF; VEGF receptor

Indexed keywords

GROWTH FACTOR; PLACENTAL GROWTH FACTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; HUMAN; HYPOXIA; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; TUMOR SUPPRESSOR GENE; VASCULAR ENDOTHELIUM;

EID: 0034493390     PISSN: 10811672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (149)

1. Induction of a fibringel investment: An early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products
2. Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs: Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression
3. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
4. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor
5. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis
6. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
7. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells
8. Vascular endothelial growth factor is a secreted angiogenic mitogen
9. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells
10. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells
11. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells
12. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro
13. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and Al in vascular endothelial cells
14. Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells
15. Vascular permeability factor/vascular endothelial growth factor inhibits anchorage-disruption-induced apoptosis in microvessel endothelial cells by inducing scaffold formation
16. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium
17. Multiple developmental roles of VEGF suggested by a LacZ-tagged allele
18. Vascular permeability factor/vascular endothelial growth factor: A multifunctional angiogenic cytokine
19. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors
20. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation
21. Human neutrophils secrete vascular endothelial growth factor
22. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation
23. Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: Implications for the biological significance of VEGF 206
24. Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of fc epsilon receptor I expression
25. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3
26. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing
27. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA
28. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix
29. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms
30. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF
31. Vascular endothelial growth factor is inactivated by binding to alpha 2-macroglobulin and the binding is inhibited by heparin
32. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency
33. Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site
34. 15N backbone assignment and secondary structure of the receptor-binding domain of vascular endothelial growth factor
35. The alpha-helical domain near the amino terminus is essential for dimerization of vascular endothelial growth factor
36. Solution structure of the heparin-binding domain of vascular endothelial growth factor
37. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain
38. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signaling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases
39. VEGFs, receptors and angiogenesis
40. Heterodimers of placenta growth factor/vascular endothelial growth factor
41. Localization of VEGF-B in the mouse embryo suggests a paracrine role of the growth factor in the developing vasculature
42. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia
43. Vascular endothelial growth factor B, a novel growth factor for endothelial cells
44. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice
45. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors
46. Restricted expression pattern of vegf-d in the adult and fetal mouse: High expression in the embryonic lung
47. c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro
48. Vascular permeability factor/ vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
49. Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused microvessels
50. Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators
51. Vascular permeability factor/ vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis
52. The vesiculo-vacuolar organelle (VVO): A distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation
53. Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels
54. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor
55. Vascular endothelial growth factor induces endothelial fenestrations in vitro
56. Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro
57. Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions
58. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF
59. VEGF is required for growth and survival in neonatal mice
60. VEGF via VEGF receptor-1 (Flt-1) mimics preeclamptic plasma in inhibiting uterine blood vessel relaxation in pregnancy: Implications in the pathogen- esis of preeclampsia
61. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placental growth factor in monocyte activation and chemotaxis
62. Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration
63. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor
64. Mitogenic activity of vasculotropin for peripheral human lymphocytes
65. Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor
66. VAS/VEGF induces differentiation in cultured osteoblasts
67. Vascular endothelial growth factor stimulates Schwann cell invasion and neovascularization of acellular nerve grafts
68. Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells
69. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
70. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
71. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
72. Characterization of the receptors for vascular endothelial growth factor
73. Characterization of the VEGF binding site on the Flt-1 receptor
74. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor
75. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis
76. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
77. Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent
78. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor
79. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice
80. Signal relays in the VEGF system
81. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
82. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
83. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
84. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (Flt-1) pre-mRNA is important for the regulation of VEGF activity
85. Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by ELISA
86. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation
87. Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1
88. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
89. Vascular endothelial growth factor is essential for corpus luteum angiogenesis
90. Identification of a vascular endothelial growth factor (VEGF) antagonist, sFlt-1, from a human hematopoietic cell line NALM-16
91. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells
92. Placenta growth factor. Potentiation of vascular growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR
93. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development
94. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinase VEGF receptor 2 (FLK) and VEGF receptor 3 (Flt-4)
95. Proteolytic processing regulates receptor specificity and activity of VEGF-C
96. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases
97. Vascular endothelial growth factor C induces angiogenesis in vivo
98. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancers
99. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3
100. A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability
101. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development
102. Requisite role of angiopoietin-1, a ligand for the Tie2 receptor, during embryonic angiogenesis
103. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
104. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
105. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia
106. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia
107. Molecular and biological properties of vascular endothelial growth factor
108. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation
109. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein
110. The von Hippel-Lindau tumor supppressor protein: New perspectives
111. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways
112. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression
113. Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: Rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth
114. Stimulation by thyroid-stimulating hormone and Graves' immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo
115. Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines
116. On the mechanism of thrombin-induced angiogenesis
117. AB
118. Stretch-induced VEGF expression in the heart
119. Mechanical stretch induces vascular permeability factor in human mesangial cells: Mechanisms of signal transduction
120. Mechanotransduction in response to shear stress. Roles of receptor tryosine kinases, integrins, and Shc
121. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway: Requirement for Flk-1/KDR activation
122. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells
123. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression
124. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia
125. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin
126. Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression
127. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma
128. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features
129. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer
130. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer
131. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis
132. Serum vascular endothelial growth factor is often elevated in disseminated cancer
133. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease
134. Elevated levels of angiogenic cytokines in the plasma of cancer patients
135. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer
136. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions
137. Markedly elevated levels of vascular endothelial growth factor in malignant ascites
138. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy
139. Vascular endothelial growth factor and its correlation with superficial bladder cancer recurrence rates and stage progression
140. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology
141. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood
142. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: Implications for measurement of circulating VEGF levels in clinical disease
143. A sensitive fluorometric enzyme-linked immunosorbent assay that measures vascular endothelial growth factor165 in human plasma
144. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor
145. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo?
146. Platelets and VEGF blood levels in cancer patients
147. Microautoradiographic quantitation of vascular endothelial growth factor mRNA levels in human prostate specimens containing normal and neoplastic epithelium
148. Quantitative RT-PCR assay for VEGF mRNA in human tumors in the kidney
149. Simultaneous in vivo quantitation of vascular endothelial growth factor mRNA splice variants